C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis.
about
Once-Monthly Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Hemodialysis-Dependent Chronic Kidney Disease: Pooled Data from Phase III Trials.Methoxy polyethylene glycol-epoetin beta for the treatment of anemia associated with chronic renal failure.Biosimilar erythropoiesis-stimulating agents and the risk of developing anti-drug antibodies-a systematic review.
P2860
C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 September 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis.
@en
C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis.
@nl
type
label
C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis.
@en
C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis.
@nl
prefLabel
C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis.
@en
C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis.
@nl
P2093
P2860
P1476
C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis.
@en
P2093
Beatriz Espinoza
Carlos Henríquez
Elizabeth De Francesco-Daher
Emma Schwedt
Ignacio Villanueva
Kleyton Bastos
Luis Antonio Lucarelli
Ricardo Correa-Rotter
Roberto Pecoits Filho
Ruben Schiavelli
P2860
P304
P356
10.1007/S11255-012-0272-3
P577
2012-09-19T00:00:00Z